Drug Profile
Research programme: Helicobacter infections - BTG/CHUV
Alternative Names: Helicobacter infections research programme - BTG/CHUVLatest Information Update: 01 May 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Helicobacter infections
Most Recent Events
- 20 Jun 2000 Available for licensing (http://www.btgplc.com)
- 20 Jun 2000 New profile
- 20 Jun 2000 Preclinical development for Helicobacter infections in Switzerland (PO)